Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794793 · ClinicalTrials.gov registry record · Phase 4
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
A Phase 4 study, sponsored by Recordati Group.
- Completed
- Registry status
- Phase 4
- Development phase
- 337
- Enrollment target
NCT01794793 is a Phase 4 study that has completed, run by Recordati Group. The registered enrollment target is 337 participants.
The verdict
NCT01794793, a Phase 4 study, has completed, sponsored by Recordati Group.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 337 participants
- Enrollment target
Study Summary
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
Interventions
- DRUG Cabergoline
- DRUG Pasireotide
- DRUG Pasireotide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2013-06-10 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794793
The ClinicalTrials.gov registry entry for NCT01794793 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 337 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recordati Group, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cabergoline is the first listed.
NCT01794793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01794793 about?
NCT01794793 is a clinical study titled "Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies". The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
What is the current status of trial NCT01794793?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 337 participants. The study started on 2013-06-10. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT01794793?
The interventions under investigation include: Cabergoline (DRUG), Pasireotide (DRUG), Pasireotide LAR (DRUG).
Who is sponsoring clinical trial NCT01794793?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.